Misplaced Pages

Vilanterol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Asthma drug – β2 adrenoreceptor agonist Pharmaceutical compound
Vilanterol
Clinical data
License data
Pregnancy
category
  • AU: B3
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 4-{(1R)-2-ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.217.751 Edit this at Wikidata
Chemical and physical data
FormulaC24H33Cl2NO5
Molar mass486.43 g·mol
3D model (JSmol)
SMILES
  • c1cc(c(c(c1)Cl)COCCOCCCCCCNC(c2ccc(c(c2)CO)O)O)Cl
InChI
  • InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
  • Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N

Vilanterol is an ultra-long-acting β2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.

Vilanterol is available in following combinations:

See also

  • Salmeterol—the long-acting β2-adrenergic receptor agonist from which vilanterol was derived.

References

  1. "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. Retrieved 10 May 2013.
  2. McKeage K (September 2014). "Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease". Drugs. 74 (13): 1509–22. doi:10.1007/s40265-014-0269-6. PMID 25074268. S2CID 29379731.
  3. Syed YY (March 2015). "Fluticasone furoate/vilanterol: a review of its use in patients with asthma". Drugs. 75 (4): 407–18. doi:10.1007/s40265-015-0354-5. PMID 25648266. S2CID 24563680.
  4. Zealand (www.bka.co.nz), Site designed and developed by bka interactive ltd, Auckland, New (22 June 2019). "Fluticasone and vilanterol | Health Navigator NZ". Health Navigator New Zealand.{{cite web}}: CS1 maint: multiple names: authors list (link)
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products


Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: